Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,772 shares of the biopharmaceutical company’s stock after buying an additional 6,815 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Gilead Sciences were worth $10,324,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in GILD. Swedbank AB grew its holdings in shares of Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after buying an additional 189,622 shares during the last quarter. OneDigital Investment Advisors LLC boosted its holdings in Gilead Sciences by 5.1% in the third quarter. OneDigital Investment Advisors LLC now owns 32,416 shares of the biopharmaceutical company’s stock valued at $2,718,000 after purchasing an additional 1,580 shares during the last quarter. Coastline Trust Co purchased a new stake in Gilead Sciences in the third quarter valued at $122,000. Natixis Advisors LLC boosted its holdings in Gilead Sciences by 18.1% in the third quarter. Natixis Advisors LLC now owns 169,363 shares of the biopharmaceutical company’s stock valued at $14,199,000 after purchasing an additional 25,912 shares during the last quarter. Finally, KPP Advisory Services LLC purchased a new stake in Gilead Sciences in the third quarter valued at $206,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $111.44 on Monday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $138.78 billion, a price-to-earnings ratio of 301.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The firm has a 50 day simple moving average of $101.82 and a 200-day simple moving average of $92.92. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Oppenheimer upped their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Bank of America increased their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Finally, DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.